Item 8.01 Other Events.
On July 20, 2020, Orchard Therapeutics plc issued a press release announcing
that it had received both orphan drug designation and rare pediatric disease
designation from the U.S Food and Drug Administration for OTL-203, an ex vivo
autologous hematopoietic stem cell gene therapy in development for the treatment
of mucopolysaccharidosis type I (MPS-I). A copy of the press release is attached
as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by
reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
99.1 Press release dated July 20, 2020
104 Cover page interactive data file (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ORCHAR 
